CAPR - CONSENSUS CO - Capricor Therapeutics

Capricor Therapeutics (CAPR) relies on California-based cell product manufacturing capacities, expanding production volumes through partnerships with biopharmaceutical behemoths. This price action chart on GURU.Markets shows that the current figure is 33.62. The business utilizes costly cryogenic delivery to preserve biomaterials, which ensures therapy safety and creates a high barrier to entry for new market players.

The consensus forecast represents the aggregated fair value of an asset, calculated as the arithmetic mean of target prices from leading investment houses to filter out market noise. By analyzing the average market target valuation of the stock, an investor compares expert expectations with the potential of Deramiocel, where the patent-protected Duchenne therapy and the success of final clinical phases determine the future cash flow of Capricor Therapeutics (CAPR).